TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02403297

Intervention type: DEVICE
Intervention: Quik Check PD
Description: The device is not an intervention. It is a device to determine if MMP-8 is present in a subjects saliva.

Intervention type: DEVICE
Intervention: Quik Check PD
Description: The device is not an intervention. It is a device to determine if MMP-8 is present in a subjects saliva.

Intervention type: DEVICE
Intervention: Quik Check PD
Description: The device is not an intervention. It is a device to determine if MMP-8 is present in a subjects saliva.
Study: NCT02262793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA/ER-DP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA/ER-DP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA/ER-DP
Study: NCT04375683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumatinib
Description: Flumatinib 600mg per day, taken on empty stomach
Study: NCT02165865

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: upper extremity/ hand transplantation
Description: hand transplant on unilateral dominant hand or bilateral upper extremity amputees
Study: NCT04068636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radioactive tracer injection via flexible endoscopy and SPECT scan for visualization of lymph nodes.
Description: Flexible endoscopy will be performed by one of two experienced head and neck surgeons. Inspection of larynx and pharynx will be performed to determine the extensions of the tumor in all directions. After local anesthesia, 2-4 peritumoral injections of Tc-99m-nanocolloïd will be given. Ten minutes after injection of Tc-99m-nanocolloïd a SPECT scan will be performed.
Study: NCT02839148

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplementation
Description: Arm 1 will be given food supplementation (FS), psychosocial stimulation (PS) and routine clinical care will be given and arm will be provided only with routine clinical care.~The control children will receive routine clinical care but no FS or PS.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplementation
Description: Arm 1 will be given food supplementation (FS), psychosocial stimulation (PS) and routine clinical care will be given and arm will be provided only with routine clinical care.~The control children will receive routine clinical care but no FS or PS.
Study: NCT01223326

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Na Cl 0.9% infusion
Study: NCT02746406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peritron+
Description: Peritron+ device to measure intravesical pressure
Study: NCT01272362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150 µg once-daily via single-dose dry powder inhaler
Study: NCT02398357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin Calcium and Warfarin
Description: Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,alone with Nadroparin Calcium 4100IU／d，subcutaneous, when taking endoscopy therapy .
Study: NCT00759902

Intervention type: DRUG
Group type: OTHER
Intervention: morphine sulfate extended-release capsules
Description: 2 x 10 mg, single-dose capsule

Intervention type: DRUG
Group type: OTHER
Intervention: morphine sulfate extended-release capsules
Description: 2 x 10 mg, single-dose capsule

Intervention type: DRUG
Group type: OTHER
Intervention: KADIAN (morphine sulfate extended-release) capsules
Description: 1 x 20 mg, single-dose capsule

Intervention type: DRUG
Group type: OTHER
Intervention: KADIAN (morphine sulfate extended-release) capsules
Description: 1 x 20 mg, single-dose capsule
Study: NCT01087671

Intervention type: DRUG
Group type: OTHER
Intervention: tafluprost
Description: prostaglandin analogue
Study: NCT02493777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD200 methylphenidate hydrochloride (MPH) Capsules
Description: HLD200 doses: 20, 40, 60, 80 or 100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01943721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VISION5 Product
Study: NCT04625595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
Description: Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
Description: Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
Description: Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
Description: Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
Study: NCT04244669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPG with Conventional Stimulation
Description: In this group, a conventional stimulation with low frequency will be tried. It will be programmed according to the usual clinical practice looking for one or more combinations of poles that allow a coverage of paraesthesia with a conventional stimulation of at least 80% of the painful area. This programming will be modified until getting not only 80% coverage but also a decrease of at least 50% in that area. It can be reprogrammed as many times as necessary during the 14-21 days of margin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPG with SCS DTM
Description: In this group the SCS DTM™ workflow will be programmed. Each SCS DTM™ program group has at least two programs with different pulse rate in the 20 to 1,200 Hz range and each having a maximum pulse width of 1ms
Study: NCT04557202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin Oral Capsule
Description: To assess the efficacy of peri-operative alpha1 blockers on improving the success rate and decreasing complications of non-stented ureteroscopic laser lithotripsy for ureteric stones.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - control group
Study: NCT03859037

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Umbilical cord milking
Description: 100 babies will have squeezing of blood from umbilical cord towards baby

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Description: 100 babies will have squeezing of blood from umbilical cord towards baby
Study: NCT01144143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: the study drug will be injected into the joint through a needle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the placebo will be injected into the joint through a needle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care: Methylprednisolone acetate
Description: Methylprednisolone acetate will be injected into the joint through a needle
Study: NCT02458872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: safety huddle alarm intervention
Description: The intervention consists of a monitor alarm dashboard that displays the numbers and types of alarms for each patient, and an accompanying checklist to guide data-driven discussion of 2-4 patients with high alarm rates.
Study: NCT02879981

Intervention type: DRUG
Intervention: Guaifenesin
Description: Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.

Intervention type: DRUG
Intervention: Sulfamethoxazole
Description: Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
Study: NCT02550444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Clonidine
Description: Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Clonidine
Description: Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
Study: NCT00753948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Nitro L-arginine-methylester (L-NAME)
Description: A non-specific inhibitor of the nitric oxide synthase enzyme.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-Nitro L-arginine-methylester (L-NAME)
Description: A non-specific inhibitor of the nitric oxide synthase enzyme.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Nitro L-arginine-methylester (L-NAME)
Description: A non-specific inhibitor of the nitric oxide synthase enzyme.
Study: NCT02257749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Rehabilitation
Description: The active rehabilitation intervention is a 6-week graded rehabilitation program, consisting of four components that are anchored in neuroscience evidence.The four components include: 1) aerobic exercise 2) coordination exercise 3) visualization 4) home program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Education Intervention (Standard Care)
Description: An initial education session will be provided by an occupational therapist related to general concussion information and outcomes, as well as strategies for symptom management following concussion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Education Intervention (Standard Care)
Description: An initial education session will be provided by an occupational therapist related to general concussion information and outcomes, as well as strategies for symptom management following concussion.
Study: NCT01847092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1722

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for AZD1722
Study: NCT00185237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menostar (estradiol transdermal delivery system)
Description: Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch
Study: NCT00825994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Description: 2 g omega-3 fatty acids (docosahexaenoic acid \[DHA\] + eicosapentaenoic acid \[EPA\]), PO \[by mouth\], qd \[every day\]
Study: NCT02409433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: Comparison of patients treated with IV lacosamide to those treated with phenytoin in the intensive care unit setting.~The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin
Description: the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day.
Study: NCT00592631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP-Continuous Positive Airway Pressure
Description: Cpap will be worn at night by subjects 6 to 7 days duration.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: SHAM will be worn at night by subjects 6 to 7 days duration.
Study: NCT04106544

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Investigational Procedures
Description: The investigational assessments will be performed
Study: NCT03918382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Patient-Reported Outcome
Description: Weekly reporting of patient-reported outcomes on a tablet for closer contact between patient and clinic during radiotherapy.
Study: NCT04751227

Intervention type: DRUG
Intervention: Modafinil
Description: 100-200 mg oral daily for for Wakefulness in the Critical Care Units
Study: NCT00878592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and life style modification
Description: This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (\<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of \~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
Study: NCT02879981

Intervention type: DRUG
Intervention: Trimethoprim
Description: Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
Study: NCT05384366

Intervention type: DRUG
Group type: OTHER
Intervention: Neoadjuvant chemotherapy
Description: doublet of taxane and carboplatin
Study: NCT01915459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A(Botulax®)
Description: IM, total dose of 360 Units at wrist flexor, elbow flexor, finger flexor, and thumb flexor based on muscle tone

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A(Botox®)
Study: NCT04860401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of tissue oxygenation with novel diagnostic near-infrared spectroscopy device (OxyPrem) (no clinical decisions based on oxygenation levels)
Description: The precision of OxyPrem is assessed by repeated measurements of tissue oxygenation and hemoglobin concentration. The accuracy of OxyPrem is assessed by comparing the measurement data to those acquired simultaneously by established NIRS devices and standard clinical monitoring devices. In substudy 1, healthy adult subjects are enrolled, in substudy 2, measurements are conducted on preterm neonates.
Study: NCT01794858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Will receive medically-necessitated ventilator support under ICU monitoring with core temperatures ≥36°C and severe acute pancreatitis defined as either a Ranson Score ≥7, a CT indicating ≥50% pancreatic necrosis, or a significant deterioration in clinical status including dysfunction of two or more organ systems. All patients will receive current standard management for severe acute pancreatitis and a standardized protocol for application of therapeutic hypothermia and rewarming. Our primary endpoints are organ-specific cardiovascular, respiratory, hematological, renal, and metabolic dysfunction as measured at 28 days. Logistic Organ Dysfunction Scores will be compared before and after therapeutic hypothermia, establishing day 4 versus day 1 changes in LOD.
Study: NCT02919449

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-NIS
Description: This is an open label single ascending dose phase I study designed to determine the safety profile and MTD after IT administration of a single dose of MV-NIS in combination with Atezolizumab in patients with metastatic NSCLC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered every 3 weeks
Study: NCT04147494

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 FAPi-46
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled PSMA-11
Description: Given IV
Study: NCT02451540

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: HRCT scan
Description: HRCT scan of thorax, at baseline and after 3 months

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: HRCT scan
Description: HRCT scan of thorax, at baseline and after 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Roflumilast
Description: Placebo, once a day in the morning during 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: Roflumilast, once a day in the morning during 3 months
Study: NCT01425229

Intervention type: DRUG
Intervention: Bosentan
Description: * Administration of bosentan: 1 x 125 mg p.o. on day 1, 2 x 125 mg p.o. on day 2-14~* Administration of clarithromycin: 2 x 500 mg p.o. on day 11-14
Study: NCT02248857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UMS Strategy
Description: Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UMS Strategy
Description: Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Texting Reminders
Description: In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
Study: NCT04147494

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Given IV
Study: NCT00809068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate and tibolone
Description: fenofibrate 160mg daily 8 weeks tibolone 2.5mg daily 23 weeks

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: tibolone
Description: tibolone 2.5 mg daily 23 weeks
Study: NCT02040831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV LID ΔM2-2 Vaccine
Description: 10\^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
Study: NCT02799875

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher permissive hypercapnia
Description: * pCO2 ≥ 60mmHg with an upper limit ≤ 75mmHg;~* pH ≥ 7.20 from a capillary or arterial blood sample;

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower Permissive Hypercapnia
Description: * pCO2 ≥ 40mmHg with an upper limit ≤ 55mmHg;~* pH ≥ 7.25 from a capillary or arterial blood sample;
Study: NCT02631291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral self-monitoring
Description: Behavioral self-monitoring will teach older adults to pay attention to their daily lifestyle practices and the conditions in which they occur. Behavioral self-monitoring is crucial for detecting change early, thereby preventing complications (mental illness symptom burden) that are associated with disruptions in healthy lifestyle practices. The steps of behavioral self-monitoring include: (1) selecting a goal, (2) paying attention to some aspect of behavior, and (3) recording some details of that behavior in a diary.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral self-monitoring + Motivational interviewing
Description: Participants will receive the same Behavioral self-monitoring intervention; participants in this condition will interact with a 'lifestyle coach' about their recorded behaviors, weekly. The lifestyle coach will use motivational interviewing to enhance older adults' confidence and intrinsic motivation to engage in healthy lifestyle practices.
Study: NCT02927730

Intervention type: OTHER
Intervention: no interventions
Description: no interventions

Intervention type: OTHER
Intervention: no interventions
Description: no interventions
Study: NCT01154491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Ferinject®: Ferric carboxymaltose: 2 vials of 10 mL containing each 500 mg iron, diluted in 250 mL normal saline for injection. Study drug to be administered by infusion immediately after preparation.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Ferinject®: Ferric carboxymaltose: 2 vials of 10 mL containing each 500 mg iron, diluted in 250 mL normal saline for injection. Study drug to be administered by infusion immediately after preparation.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Erythropoetin: 40,000 units subcutaneous (unique dose).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for ferric carboxymaltose: 250 mL normal saline for intravenous administration.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection.
Study: NCT00410189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474
Description: 300 mg by mouth daily for 28 Days.
Study: NCT03729635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoral-intercostal fascial plane block (PIFB)
Description: Local anesthetic is infiltrated into the fascial plane between pectoralis major and the intercostal muscles lateral to the sternum to anesthetize the anterior cutaneous branches of the intercostal nerves.
Study: NCT00443118

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-piece resuscitator Neopuff TM
Description: Positive pressure ventilation will be performed with Neopuff® with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self Inflating Bag with PEEP
Description: Positive pressure ventilation will be performed with Self Inflating Bag with PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self Inflating Bag without PEEP
Description: Positive pressure ventilation will be performed with Self Inflating Bag without PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.